Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Fibrobiologics (FBLG) · oqro.io/stocks/FBLG · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Have Fibrobiologics insiders bought shares recently?
No open-market purchase by an insider of Fibrobiologics was filed in the last 90 days. The latest on record was on May 27, 2025.
How often do Fibrobiologics insiders buy and sell shares?
Since 2024, Fibrobiologics insiders reported 3 open-market purchases and 0 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2025.
Who is selling Fibrobiologics stock?
No open-market sale by an insider of Fibrobiologics (FBLG) was filed with the SEC in the last 90 days.
Do members of Congress trade FBLG?
No trade in Fibrobiologics (FBLG) was disclosed by a member of Congress in the last 12 months.
When does Fibrobiologics report its next results?
Fibrobiologics's next results are expected on Feb 22, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−89.1% (−$5.79) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $6.49 on Nov 20, 2025 to $0.705 on Nov 20, 2026 (−89.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$-2$2$4$6$8$10$0.705
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Houston, Tx.
Last 12 months
−89.1%
S&P 500 +5.7% over the same dates
Market value
$4.69M
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 334K shares sold short (5.0% of shares outstanding), +1.1% vs the previous count, 3.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Free cash flow, last 12 months
−$13.6M
This quarter −$2.77M, a year earlier −$3.98M
Net debt
—
Debt —, cash $1.17M, at Sep 30, 2026
Net income, last 12 months
−$16.4M
Operating loss: profit did not cover interest
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Late-stage clinical trials
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in diabetic foot ulcer (dfu). The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Fibrobiologics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 1 open-market purchase (about $17K, in 1 filing) and 0 open-market sales (about $0, in 0 filings). (Fibrobiologics on OQRO)
Contracts, lobbying and filings. ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the T..." (Phase 2, status recruiting), was updated on Aug 26, 2026, with primary completion listed for 2026-12-31. FINRA short interest for FBLG on the settlement date of Oct 30, 2026 was 334,123 shares (+1.08% on the previous report), about 3.12 days of average volume.
Company reports, price and press. Fibrobiologics filed a Form 8-K on Aug 24, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors. The company's own opening sentence of that report reads: "On August 20, 2026, the Board of Directors (the 'Board') of FibroBiologics, Inc. (the 'Company') appointed Leigh Steinberg as a Class II director of the Board, effective August 20, 2026, to serve until the expiration of his term..."
Who holds it. 16 funds reported a stake in Fibrobiologics in their 13F for Q2 2026. The largest by value: Cascade Financial Partners, LLC (38.3% of the value reported), Fund Evaluation Group, LLC (18.2% of the value reported), GEODE CAPITAL MANAGEMENT, LLC (10.7% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Fibrobiologics filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 1 open-market purchase (about $17K, in 1 filing) and 0 open-market sales (about $0, in 0 filings).
Contracts, lobbying and filings
ClinicalTrials.gov shows 1 study sponsored by the company updated in the period; the latest, "Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the T..." (Phase 2, status recruiting), was updated on Aug 26, 2026, with primary completion listed for 2026-12-31.
FINRA short interest for FBLG on the settlement date of Oct 30, 2026 was 334,123 shares (+1.08% on the previous report), about 3.12 days of average volume.
Company reports, price and press
Fibrobiologics filed a Form 8-K on Aug 24, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On August 20, 2026, the Board of Directors (the 'Board') of FibroBiologics, Inc. (the 'Company') appointed Leigh Steinberg as a Class II director of the Board, effective August 20, 2026, to serve until the expiration of his term..."
Fibrobiologics filed a Form 8-K on Jul 24, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
The company's own opening sentence of that report reads: "On July 22, 2026, FibroBiologics, Inc. (the 'Company') received a Staff Determination letter (the 'Staff Determination') from the Listing Qualifications Department of The Nasdaq Stock Market LLC ('Nasdaq') notifying the Company t..."
Fibrobiologics filed a Form 8-K on Jul 9, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "On July 2, 2026, Matt Link notified FibroBiologics, Inc. (the 'Company') that he was resigning from the Board of Directors (the 'Board'), effective as of July 2, 2026."
Press coverage listed by Finnhub: "FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts" (Yahoo, Nov 16, 2026).
Press coverage listed by Finnhub: "Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications" (Yahoo, Nov 12, 2026).
Press coverage listed by Finnhub: "FibroBiologics Announces Update On Its Intellectual Property Portfolio" (Yahoo, Nov 12, 2026).
FBLG closed at $0.84 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.9441 to $0.84, a change of −11.0%.
Who holds it
16 funds reported a stake in Fibrobiologics in their 13F for Q2 2026. The largest by value: Cascade Financial Partners, LLC (38.3% of the value reported), Fund Evaluation Group, LLC (18.2% of the value reported), GEODE CAPITAL MANAGEMENT, LLC (10.7% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Latest annual report filed Feb 24, 2026, compared with the one filed Mar 31, 2025. Read the filing
New risk factors in the latest annual report (1 heading)
Our management and principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
No longer listed (1 heading from the year before)
We are a “controlled company” within the meaning of the Nasdaq Stock Market Rules because our insiders beneficially own more than 50% of the voting power of our outstanding voting securities.
Legal proceedings (Item 3)
From time to time, we may be involved in legal proceedings relating to intellectual property, commercial, employment and other matters arising in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position, or cash flows. There are no legal proceedings at this time.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Red flags in its filings
Jul 24
Notice of delisting or failure to meet listing rules
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “Overview”, in the company's words
We are a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Our most advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. We have completed our IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing.
What the section covers (27 headings)
Overview
Components of Results of Operations
Revenue
Research and Development Expenses
General, Administrative and Other Expenses
Interest Expense
Statements of Operations
Results of Operations
Comparison of Fiscal Years December 31, 2025 and 2024
Commitment Fee Expenses
Placement agent and tail fee expenses
Gain on termination of warrant and commitment fee liabilities
Other income/(expense)
Interest income
And 13 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Insider buying and selling since 2024
Insiders of Fibrobiologics reported 3 open-market purchases and 0 sales since 2024; purchases in 2 different years, most recently 2025.
Year
Bought
Sold
2025
$17K1×1 trade
—
2024
$35K2×2 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Off-exchange trading: 50.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.2% on ATS, 46.5% with other brokers), below its 26-week average of 53.3%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (16.6%), POSIT (8.2%), LEVEL ATS (7.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
When insiders usually buy
Last results
—
Next results, expected
Feb 22, 2027
Purchases after results
Not enough history
From Fibrobiologics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Fibrobiologics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
On the public record for Fibrobiologics over the 12 months to Nov 21, 2026: 1 clinical trial.